Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "PharmPro" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about PharmPro for you to read. Along with our medical data and news we also list PharmPro Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmPro Companies for you to search.
NewsPharmaceutical patent litigation filings have declined for the first time in three years, according to Lex Machina's Hatch-Waxman/ANDA Litigation Report.
Bristol-Myers Squibb reports first quarter financial results. The company also cited positive opinions from the Committee for Medicinal Products for Human Use (CHMP) for advanced bladder and head and neck cancers in Europe.
NewsSales of Xarelto climbed by 19.6 percent on a currency-adjusted basis, due primarily to higher volumes in Europe and Japan. In addition, Bayer once again significantly expanded its business with the eye medicine Eylea.
NewsAnglo-Swedish drugmaker AstraZeneca says first-quarter revenue fell amid declining sales of cholesterol treatment Crestor, which lost patent protection last year, but the company remains optimistic over new cancer treatments.
NewsAnglo-Swedish drugmaker AstraZeneca says first-quarter revenue fell amid declining sales of cholesterol treatment Crestor, which lost patent protection last year.
NewsCorporate Whistleblower Center urges pharmaceutical company employees to call them about possible rewards if their employer is making drugs at an unclean manufacturing facility.
NewsRecord growth for life science tech firm as manufacturing execution system (MES) adoption increases globally. MES has become Zenith Technologies' fastest growing segment and now represents almost a third of its business.
NewsMidazolam nasal spray (USL261) Phase 3 trial meets primary efficacy endpoint in patients with seizure clusters.
NewsPennsylvania's medical marijuana program remains on schedule after hundreds of applications poured in from those who want to grow, process, and dispense the drug. The goal is to issue permits by the end of June.
NewsImpax announces FDA approval and launch of a generic version of Vytorin (ezetimibe/simvastatin tablets). Commercialization activities were initiated immediately.
NewsFDA approves Xatmep, the first and only ready-to-use methotrexate oral solution. Xatmep is indicated for the treatment of acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis in pediatric patients.
NewsPharmatek adds further cGMP spray drying capacity in response to demand for improved pharmaceutical solubility. Catalent acquired Pharmatek Laboratories, Inc., in September 2016, to add early-phase drug development capabilities.
NewsOvarian cancer market to more than quadruple to $5.2 billion by 2025, says GlobalData. The key driver will be the establishment of new standard of care maintenance therapies in the first and second lines of treatment.
NewsInspirion Delivery Sciences receives FDA approval for RoxyBond (oxycodone hydrochloride) tablets CII, the first and only immediate release opioid analgesic with abuse-deterrent label claims.
NewsGlenmark Pharmaceuticals initiates clinical investigation for GBR 310, its proposed biosimilar candidate for Xolair. Study will assess its pharmacokinetics in healthy adult volunteers between 18 – 65 years of age.
NewsSanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection. The monthly dosing schedule now is approved in both the United States and European Union.
NewsSanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection. The monthly dosing schedule now is approved in both United States and European Union.
NewsDomain Therapeutics and Pfizer Inc. enter into collaboration agreement on bioSensAll. Proprietary technology will be used to profile signaling of mutant G protein-coupled receptors in order to improve and accelerate the validation of novel drug targets.
NewsThe company plans to provide guidance and counsel to biotech startups, along with access to a state-of-the-art collaborative laboratory.
NewsNovartis delivered sales growth across all divisions (constant currency) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued.
NewsAn $857.6 million charge tied to the company's purchase of CoLucid Pharmaceuticals countered revenue growth of 7 percent spurred by the insulin Humalog and some newer drugs.
NewsThe appeal involves a 2016 ruling by the California Supreme Court that found that out-of-state plaintiffs could sue the drug company for injuries even though the company is not based in the state and the drugs were not purchased or ingested in the state.
NewsIn the deal, Merck receives an upfront purchase price, milestone payments, and royalties on potential product sales. Closing is expected to take place in the second half of 2017.
NewsThe acquisition is expected to enhance and diversify Fresenius Kabi’s business and portfolio. The deal, which is expected to close in early 2018, is valued at approximately $4.3 billion plus the assumption of debt.
NewsJapan’s Sawai Pharmaceutical to acquire the generics business of U.S. Upsher-Smith Laboratories. The $1.05 billion deal is expected to close near the end of June 2017.